Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Reduction in bradykinin generation during leukocytapheresis using novel cellsorba(TM) CS-180S: Effects of changing the filling solution.

Yamada R, Kusaoi M, Murayama G, Yasui M, Hishinuma R, Nemoto T, Hohtatsu K, Kageyama M, Kawamoto T, Sugimoto K, Sekiya F, Kon T, Ogasawara M, Kempe K, Yamaji K, Tsuda H, Takasaki Y.

J Clin Apher. 2014 Apr;29(2):90-6. doi: 10.1002/jca.21297. Epub 2013 Sep 11.

PMID:
24023037
2.

Effect of various anticoagulant agents on large-volume leukocytapheresis using new Cellsorba CS-180S Filter.

Hohtatsu K, Yamaji K, Yamada R, Oda K, Kageyama M, Kusaoi M, Onuma S, Kawamoto T, Sugimoto K, Sekiya F, Kon T, Ogasawara M, Kempe K, Tsuda H, Takasaki Y.

Ther Apher Dial. 2011 Aug;15(4):355-9. doi: 10.1111/j.1744-9987.2011.00962.x.

PMID:
21884469
3.

Selection of anticoagulants for leukocytapheresis therapy in cases of active ulcerative colitis.

Kanke K, Hoshino M, Tominaga K, Nakano M, Terano A, Hiraishi H.

Blood Purif. 2007;25(4):370-6. Epub 2007 Aug 30.

PMID:
17785966
4.

Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis.

Eguchi K, Saito K, Kondo M, Hidaka T, Ueki Y, Tanaka Y; LCAP Investigators in Kyushu College of Rheumatology (LIKCR).

Mod Rheumatol. 2007;17(6):481-5. Epub 2007 Dec 20.

PMID:
18084700
5.

Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study.

Sawada K, Ohdo M, Ino T, Nakamura T, Numata T, Shibata H, Sakou J, Kusada M, Hibi T.

Ther Apher Dial. 2016 Apr;20(2):197-204. doi: 10.1111/1744-9987.12357. Epub 2016 Jan 14.

PMID:
26771066
6.

Efficacy of high-throughput leukocytapheresis for rheumatoid arthritis with a reduced response to infliximab.

Sakai Y, Sakai S, Otsuka T, Ohno D, Murasawa T, Munakata K, Mizuno K.

Ther Apher Dial. 2009 Jun;13(3):179-85. doi: 10.1111/j.1744-9987.2009.00657.x.

PMID:
19527463
7.

Investigation of the clinical effect of large volume leukocytapheresis on methotrexate-resistant rheumatoid arthritis.

Onuma S, Yamaji K, Kempe K, Ogasawara M, Ogawa T, Yang K, Kanai M, Tsuda H, Takasaki Y.

Ther Apher Dial. 2006 Oct;10(5):404-11.

PMID:
17096694
8.

Effectiveness of leukocytapheresis in suppressing the occurrence of surgical site infections following surgery for ulcerative colitis.

Itabashi M, Ikeuchi H, Araki T, Kono T, Nakamura T, Takesue Y, Kameoka S, Kusunoki M.

Surg Today. 2008;38(7):609-17. doi: 10.1007/s00595-007-3685-3. Epub 2008 Jul 9.

PMID:
18612785
9.

Cellsorba.

Shibata H, Kuriyama T, Yamawaki N.

Ther Apher Dial. 2003 Feb;7(1):44-7.

PMID:
12921114
10.
11.

Safety and tolerability of a modified filter-type device for leukocytapheresis using ACD-A as anticoagulant in patients with mild to moderately active ulcerative colitis. Results of a pilot study.

Muratov V, Lundahl J, Mandic-Havelka A, Elvin K, Ost A, Shizume Y, Furuya K, Löfberg R.

J Clin Apher. 2010;25(5):287-93. doi: 10.1002/jca.20255.

PMID:
20806415
12.

Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications.

Ashizuka S, Nishiura R, Ishikawa N, Yamaga J, Inatsu H, Fujimoto S, Eto T.

Ther Apher Dial. 2006 Feb;10(1):54-8.

PMID:
16556137
13.

Recent understanding of leukocytapheresis (LCAP) for the treatment of inflammatory bowel disease.

Mitsuyama K, Yamasaki H, Kuwaki K, Takedatsu H, Sata M.

Curr Pharm Des. 2009;15(18):2110-9. Review.

PMID:
19519448
14.

Safety and efficacy of high-dose leukocytapheresis in patients with refractory asthma.

Ishizuka T, Hisada T, Hatori M, Koike A, Hanabuchi K, Matsuzaki S, Kamide Y, Utsugi M, Aoki H, Yoshino R, Yanagitani N, Koga Y, Ono A, Kaira K, Sunaga N, Dobashi K, Tsuburai T, Akiyama K, Yamada M, Suzuki K, Mori M.

Inflamm Res. 2014 Sep;63(9):789-96. doi: 10.1007/s00011-014-0753-1. Epub 2014 Jul 8.

PMID:
25001341
15.

Recruitment of immature neutrophils in peripheral blood following leukocytapheresis therapy for rheumatoid arthritis.

Okawa-Takatsuji M, Nagatani K, Nakajima K, Itoh K, Kano T, Nagashio C, Takahashi Y, Aotsuka S, Mimori A.

J Clin Apher. 2007;22(6):323-9.

PMID:
18095302
16.

Leukocytapheresis using a leukocyte removal filter.

Shirokaze J.

Ther Apher. 2002 Aug;6(4):261-6. Review.

PMID:
12164794
17.

Efficacy of filtration leukocytapheresis on rheumatoid arthritis with vasculitis.

Hidaka T, Suzuki K.

Ther Apher. 1997 Aug;1(3):212-4.

PMID:
10225740
18.

Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with Cellsorba in patients with active ulcerative colitis.

Fukunaga K, Kamikozuru K, Yokoyama Y, Hida N, Ohda Y, Takeda N, Yoshida K, Iimuro M, Kikuyama R, Kato K, Nagase K, Nakamura S, Miwa H, Matsumoto T.

J Clin Apher. 2011 Dec;26(6):326-31. doi: 10.1002/jca.20314. Epub 2011 Nov 14.

PMID:
22083887
19.

Leukocytapheresis for rheumatic disease.

Hidaka T, Suzuki K.

Ther Apher Dial. 2003 Apr;7(2):161-4. Review.

PMID:
12918938
20.

Leukocytapheresis therapy by extracorporeal circulation using a leukocyte removal filter.

Suemitsu J, Yoshida M, Yamawaki N, Yamashita Y.

Ther Apher. 1998 Feb;2(1):31-6. Review.

PMID:
10227786

Supplemental Content

Support Center